期刊文献+

微调五号方或联合生物反应调节剂对Ⅲ、Ⅳ期肾癌患者生存质量影响的临床研究 被引量:5

The Clinical Research of WD-5 with Biological Response Modifiers with IFN-α2b& IL-2 in the Quality of Life of Renal Cell Carcinoma Patients of Stage Ⅲ、Ⅳ
原文传递
导出
摘要 目的:观察微调五号方(WD-5)或WD-5联合生物反应调节剂(IL-2和IFN-α2b)对Ⅲ、Ⅳ期肾癌患者生存质量的影响。方法:Ⅲ、Ⅳ期肾癌患者共40例,按随机数字表法分为治疗组(WD-5+生物反应调节剂)及对照组(单纯生物反应调节剂),治疗2个疗程后观察两组患者治疗前后实体瘤大小、临床常见症状改善情况、Karnofsky体力状况评分、细胞免疫功能水平、肿瘤标志物水平、生命质量评分,以及治疗毒副反应。结果:WD-5+生物反应调节剂在缓解临床症状、提高卡氏评分、提高细胞免疫功能、降低肿瘤标志物水平、提高患者生命质量、减轻生物反应调节剂治疗的毒副反应方面优于单纯使用生物反应调节剂。结论:WD-5联合IL-2和IFN-α2b治疗Ⅲ、Ⅳ期肾细胞癌,能够缓解患者临床症状和体征,提高患者细胞免疫功能,改善体力状况,提高生命质量,且治疗毒副反应减轻。 Object: To elaluate the quality of life of traditional Chinese medicine( WD-5) and biological response modifiers with IL-2 IFN-α2b on renal cell cancer patients of stage Ⅲ、Ⅳ. Methods: 40 renal cell carcinoma cases of stageⅢ、Ⅳ were randomly assigned into 2 groups. According to random number table,enlisted patients were divided into observation group and control group.The combined treated group were given WD-5 and biological response modifiers with IL-2 IFN-α2b,and the control group were treated with biological response modifiers with IL-2 IFN-α2b scheme only. The efficacy was evaluated after 2 courses according to RECIST( Response Evaluation Critera In Solid Tumors) criteria,and the clinical evaluating indexes such as clinical symptom amelioration,Karnofsky score,tumor marks,The T lymphocyte subsets and the quality of life( QOL) and the toxicity and feasible with tolerable adverse reactions. Result:The trail group displayed more effective lightening the clinical symptoms,enhancing the quality of life and the physical strength( KPS score),improving immunologic function,reducing the level of tumor marker,raising patients' quality of life and reducing toxicity.
出处 《中华中医药学刊》 CAS 北大核心 2016年第2期447-450,共4页 Chinese Archives of Traditional Chinese Medicine
基金 无锡市卫生局卫生科技项目(201206)
关键词 微调五号方 生物反应调节剂 肾癌 中医药 临床研究 WD-5 biological response modifiers renal cell carcinoma integration of traditional Chinese TCM clinical research
  • 相关文献

参考文献8

  • 1周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601~610.
  • 2Eble JN, Sauter G, Epstein JI, et al. World health organization classification of tumours. Pathology & genetics. Tumours of the urinary system and male genital organs [ M ]. Lyon: IARC Press, 2004:9 - 43.
  • 3Stephen B, April G, David R, et al. Cancer Staging Manual Seventh Edition [ M ]. America : Springer Science and Business Media LLC (SBM) ,2010:43.
  • 4郭军,马建辉.中国肾细胞癌诊治指南内科治疗解读[J].临床肿瘤学杂志,2008,13(8):748-751. 被引量:11
  • 5万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1232
  • 6The NCI Common Terminology Criteria for Adverse Events V3.0 [ EB/OL], http ://ctep. Cancer. gov/protol Development/elec- tronic applications/docs/ctcaev3, pdf.
  • 7吴阶平.泌尿外科[M].济南:山东科学技术出版社,2009:454-456.
  • 8Mulder P, Figlin R, Dekemion JB, et al. Renal cell carcinoma recent progress and future diroelion [ J]. Career Res, 1997, 57 5189 -5195.

二级参考文献25

  • 1Johnson JR,Temple R. Food and drug administration requirements for approval of new anti-cancer drugs[J]. Cancer Treat Rep, 1985,69(10) : 1155-1157.
  • 2Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993,85 (5) : 365-376.
  • 3Aaronson NK, Cull A, Kaasa S, et al. The EORTC modular approach to quality of life assessment in ontology [J]. Int J Ment Health, 1994,23 (4):75-96.
  • 4Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy[ J]. J Clin Oncol, 1994,12:206 - 212.
  • 5Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow-up of renal cell carcinoma based on pathological stage[J]. J Urol, 1995, 154:28-31.
  • 6Rouviere O, Bouvier R, Negrier S, et al. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up[ J]. Nat Clin Pract Oncol, 2006, 3: 200 - 213.
  • 7Messing EM, Manola J, Wilding G, et al. Phase Ⅲ study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial[J]. J Clin Oncol, 2003, 21 (7):1214- 1222.
  • 8Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial [ J ]. J Clin Oncol, 2003,21:3133 - 3140.
  • 9Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma [ J ]. J Clin Oncol, 2002,20 ( 1 ) : 289 - 296.
  • 10Coppin C, Porzsoh F, Awa A, et al. Immunotherapy for advanced renal cell cancer [ J ]. Cochrane Database Syst Rev, 2006,2:61 - 65.

共引文献1390

同被引文献59

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部